DDInter1351 DDInter1676
Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's disease is often the result of ACTH hypersecretion secondary to a pituitary tumor, and surgical resection of the tumour is generally the treatment of choice. As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery has not been curative. Osilodrostat is manufactured by Novartis under the brand name Isturisa. It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Osilodrostat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Osilodrostat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Osilodrostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zileuton
Osilodrostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Elagolix
Osilodrostat {u} may lead to a major life threatening interaction when taken with {v} Tizanidine
Osilodrostat {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Osilodrostat may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Osilodrostat may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Zileuton
Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Osilodrostat may lead to a major life threatening interaction when taken with Tizanidine
Osilodrostat may lead to a major life threatening interaction when taken with Ivosidenib